[go: up one dir, main page]

NO20020037D0 - Fremgangsmåter for å unngå vektökning - Google Patents

Fremgangsmåter for å unngå vektökning

Info

Publication number
NO20020037D0
NO20020037D0 NO20020037A NO20020037A NO20020037D0 NO 20020037 D0 NO20020037 D0 NO 20020037D0 NO 20020037 A NO20020037 A NO 20020037A NO 20020037 A NO20020037 A NO 20020037A NO 20020037 D0 NO20020037 D0 NO 20020037D0
Authority
NO
Norway
Prior art keywords
procedures
weight gain
avoiding weight
avoiding
gain
Prior art date
Application number
NO20020037A
Other languages
English (en)
Other versions
NO329614B1 (no
NO20020037L (no
Inventor
Fernand Labrie
Yves Deshaies
Denis Richard
Celine Martel
Original Assignee
Endorecherce Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherce Inc filed Critical Endorecherce Inc
Publication of NO20020037D0 publication Critical patent/NO20020037D0/no
Publication of NO20020037L publication Critical patent/NO20020037L/no
Publication of NO329614B1 publication Critical patent/NO329614B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO20020037A 1999-07-06 2002-01-04 Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et medikament for behandling eller redusering av risiko for a utvikle insulinresistens NO329614B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14240799P 1999-07-06 1999-07-06
PCT/CA2000/000798 WO2001001969A2 (en) 1999-07-06 2000-07-05 Methods of treating and/or suppressing weight gain

Publications (3)

Publication Number Publication Date
NO20020037D0 true NO20020037D0 (no) 2002-01-04
NO20020037L NO20020037L (no) 2002-03-04
NO329614B1 NO329614B1 (no) 2010-11-22

Family

ID=22499734

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020037A NO329614B1 (no) 1999-07-06 2002-01-04 Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et medikament for behandling eller redusering av risiko for a utvikle insulinresistens

Country Status (25)

Country Link
US (2) US6710059B1 (no)
EP (1) EP1196163B1 (no)
JP (1) JP4790178B2 (no)
KR (1) KR101141763B1 (no)
CN (1) CN1390126B (no)
AR (1) AR034091A1 (no)
AT (1) ATE447947T1 (no)
AU (3) AU5957500A (no)
BR (1) BR0012354A (no)
CA (1) CA2376158C (no)
DE (1) DE60043305D1 (no)
DK (1) DK1196163T3 (no)
HK (1) HK1046240B (no)
HU (1) HU230543B1 (no)
IL (2) IL147485A0 (no)
MX (1) MX270786B (no)
MY (1) MY134574A (no)
NO (1) NO329614B1 (no)
NZ (1) NZ516453A (no)
PL (1) PL208972B1 (no)
RU (3) RU2327461C2 (no)
TR (2) TR200403328T2 (no)
TW (1) TWI359015B (no)
WO (1) WO2001001969A2 (no)
ZA (1) ZA200200085B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ID27922A (id) * 1998-06-11 2001-05-03 Endorech Inc KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6560217B1 (en) 1999-02-25 2003-05-06 3Com Corporation Virtual home agent service using software-replicated home agents
TR200403328T2 (tr) * 1999-07-06 2005-03-21 Endorecherche, Inc. Kilo alımını tedavi ve/veya önleme metotları.
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
SK9592002A3 (en) * 2000-01-28 2003-12-02 Endorech Inc A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit
MXPA04002249A (es) 2001-09-24 2004-06-29 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de 1,5,6,7,-tetrahidro-pirrolo[3,2-c]piridina para el tratamiento de la obesidad.
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
AU2003294185A1 (en) * 2002-12-13 2004-07-09 N.V. Nutricia Method and composition for inhibiting carbohydrate digestion
US7074779B2 (en) 2003-07-02 2006-07-11 Ortho-Mcneil Pharmaceutical, Inc. Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
CN106138065A (zh) * 2004-10-20 2016-11-23 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
US20060234993A1 (en) * 2005-04-13 2006-10-19 Eric Marchewitz Use of androstane derivatives for enhancing physical performance
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
KR20080031037A (ko) * 2005-06-29 2008-04-07 와이어쓰 결합형 에스트로겐과 바제독시펜의 제형
WO2007011708A2 (en) * 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US8298565B2 (en) 2005-07-15 2012-10-30 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
AU2007243268B2 (en) 2006-04-26 2013-06-13 Micell Technologies, Inc. Coatings containing multiple drugs
WO2008042909A2 (en) 2006-10-02 2008-04-10 Micell Technologies Inc. Surgical sutures having increased strength
CN101678388B (zh) * 2006-10-23 2013-12-11 米歇尔技术公司 用于在涂覆过程中为基底充电的保持器
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
JP5443336B2 (ja) * 2007-04-17 2014-03-19 ミセル テクノロジーズ、インコーポレイテッド 生分解性層を有するステント
CN101815540B (zh) * 2007-05-25 2015-08-19 米歇尔技术公司 用于医疗器材涂层的聚合物膜
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
BRPI0910969B8 (pt) * 2008-04-17 2021-06-22 Micell Technologies Inc dispositivo
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
WO2010111196A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Peripheral stents having layers
CA2756388C (en) * 2009-03-23 2015-10-27 Micell Technologies, Inc. Biodegradable polymers with low acidic impurity
WO2010111232A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Drug delivery medical device
EP2413847A4 (en) * 2009-04-01 2013-11-27 Micell Technologies Inc COATED STENTS
EP2419058B1 (en) 2009-04-17 2018-02-28 Micell Technologies, Inc. Stents having controlled elution
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
EP2455082A4 (en) * 2009-07-16 2012-12-19 Univ Kyushu Nat Univ Corp INSULIN-PRODUCING CELL INDUCTOR, GLUCOSE-UP AMPLIFIERS AND THERAPY AGENTS FOR DIABETES OR COMPLICATIONS IN CONNECTION WITH DIABETES
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
WO2011097103A1 (en) 2010-02-02 2011-08-11 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2580210B1 (en) 2010-06-10 2017-03-01 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
KR20140089402A (ko) 2010-06-16 2014-07-14 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
AP2014007657A0 (en) 2011-12-16 2014-05-31 Olema Pharmaceuticals Inc Novel benzopyran compounds, compositions and uses thereof
WO2014165264A1 (en) 2013-03-12 2014-10-09 Micell Technologies, Inc. Bioabsorbable biomedical implants
JP2016519965A (ja) 2013-05-15 2016-07-11 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
CA3006683A1 (en) * 2015-12-22 2017-06-29 Jiangsu Hengrui Medicine Co., Ltd. Benzopiperidine derivative, preparation method thereof and medical use thereof
US20180207097A1 (en) * 2017-01-23 2018-07-26 Government Of The United States As Represented By The Secretary Of The Air Force Non-toxic vehicle to solubilize, deliver, and obtain biological activity of steroid hormones at cell, tissue, and organ targets, in vitro and in vivo
CN114315851B (zh) * 2022-01-03 2023-10-24 安徽大学绿色产业创新研究院 一种光甘草定药物中间体的合成方法
JP7440838B1 (ja) 2023-07-06 2024-02-29 株式会社インタートレードヘルスケア 卵巣機能欠落生体の内臓脂肪蓄積抑制飲食品、及び卵巣機能欠落生体の内臓脂肪蓄積抑制薬

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504119B1 (fr) * 1981-04-17 1985-09-20 Aury Jean Pierre Beton isolant ainsi que son procede de fabrication
DE3117979A1 (de) * 1981-05-07 1983-01-20 Hoechst Ag, 6000 Frankfurt Neue(delta)1-pyrrolin-thiolactimaether und verfahren zu ihrer herstellung
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
CA2091102C (en) * 1992-03-06 2009-05-26 John R. Ii Wetterau Microsomal triglyceride transfer protein
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
NZ260790A (en) 1993-06-24 1997-06-24 Lilly Co Eli Antiestrogen compositions for treatment of diabetes mellitus
US5446061A (en) * 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5527788A (en) * 1994-01-18 1996-06-18 Louisiana State Univ. Medical Center Foundation Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5441986A (en) 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
RU2098330C1 (ru) * 1996-01-05 1997-12-10 Акционерное общество открытого типа "ХИТОН" Способ подачи и аэрозольного распылиения жидкого активного продукта и устройство для его осуществления
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5843984A (en) 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
WO1999002512A1 (en) * 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
AU8433898A (en) * 1997-07-10 1999-02-08 Novo Nordisk A/S Use of 3,4-diphenylchromans for the manufacture of a pharmaceutical composition for increasing insulin sensitivity
UA70925C2 (uk) * 1997-08-15 2004-11-15 Дюк Юнівесіті Спосіб лікування естрогенстимульованого раку
ATE218348T1 (de) * 1997-10-08 2002-06-15 Genesiscosmetics Rights & Lice Straffung und/oder verkleinerung von fettzellen- haltigen körperpartien
JP2002515431A (ja) 1998-05-15 2002-05-28 アメリカン・ホーム・プロダクツ・コーポレイション エストロゲンと組み合わせる２−フェニル−１−［４−（２−アミノエトキシ）ベンジルオキシ］インドール
ID27922A (id) 1998-06-11 2001-05-03 Endorech Inc KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU771352B2 (en) * 1999-06-18 2004-03-18 Stephen James Cordell Finishing tool
TR200403328T2 (tr) 1999-07-06 2005-03-21 Endorecherche, Inc. Kilo alımını tedavi ve/veya önleme metotları.

Also Published As

Publication number Publication date
TWI359015B (en) 2012-03-01
US8609695B2 (en) 2013-12-17
PL208972B1 (pl) 2011-07-29
JP4790178B2 (ja) 2011-10-12
WO2001001969A2 (en) 2001-01-11
AU2009200258A1 (en) 2009-02-26
MY134574A (en) 2007-12-31
ATE447947T1 (de) 2009-11-15
MX270786B (es) 2009-10-08
IL195860A (en) 2013-06-27
JP2003503446A (ja) 2003-01-28
HUP0202363A3 (en) 2005-02-28
WO2001001969A3 (en) 2001-08-02
CA2376158C (en) 2011-03-15
AU2009200258B2 (en) 2012-01-12
DE60043305D1 (de) 2009-12-24
RU2008101793A (ru) 2009-07-27
HU230543B1 (hu) 2016-11-28
NO329614B1 (no) 2010-11-22
BR0012354A (pt) 2002-04-02
AU5957500A (en) 2001-01-22
AR034091A1 (es) 2004-02-04
ZA200200085B (en) 2003-06-25
US20040034000A1 (en) 2004-02-19
EP1196163B1 (en) 2009-11-11
EP1196163A2 (en) 2002-04-17
NO20020037L (no) 2002-03-04
CA2376158A1 (en) 2001-01-11
RU2519642C2 (ru) 2014-06-20
HK1046240B (en) 2010-09-30
HUP0202363A2 (en) 2002-10-28
TR200403328T2 (tr) 2005-03-21
CN1390126A (zh) 2003-01-08
RU2327461C2 (ru) 2008-06-27
US6710059B1 (en) 2004-03-23
NZ516453A (en) 2004-04-30
MXPA02000075A (es) 2003-05-23
AU2005229713A1 (en) 2005-12-01
KR101141763B1 (ko) 2012-05-08
RU2013148518A (ru) 2015-05-10
HK1046240A1 (en) 2003-01-03
DK1196163T3 (da) 2010-03-29
TR200502284T2 (tr) 2005-08-22
RU2636498C2 (ru) 2017-11-23
PL352993A1 (en) 2003-09-22
TW200803838A (en) 2008-01-16
CN1390126B (zh) 2012-06-13
IL147485A0 (en) 2002-08-14
KR20020020776A (ko) 2002-03-15

Similar Documents

Publication Publication Date Title
NO20020037D0 (no) Fremgangsmåter for å unngå vektökning
ATE261933T1 (de) Admantan derivate
NO20000885D0 (no) 4-Fenyl-pyridin-derivater
NO20021077D0 (no) Amino-triazolopyridin-derivater
ATE263748T1 (de) Admantan-derivate
DE50010060D1 (de) Thiazolylamid-derivate
ATE257827T1 (de) Triazolderivate
DE60013127D1 (de) 5-phenyl-pyrimidine derivate
IS6128A (is) 13-Metýl-erýþrómýsín afleiður
NO20021803L (no) Isoksazolkarboksamid-derivater
ATE257148T1 (de) Propargyletherderivate
DK1154988T3 (da) Mevinolinderivater
ATE374747T1 (de) Monofluoralkylderivate
ATE317389T1 (de) 4-phenyl-pyrimidine derivate
ATE254598T1 (de) 4-hydroxybiphenylhydrazid-derivate
ATE293592T1 (de) Resorcinderivate
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
DE50009340D1 (de) Einstelleinrichtung
ATE249427T1 (de) Diacylhydrazinderivate
NO20020212L (no) 3-amino-2-benzyl-1-fenyl-propanderivater
NO20022867D0 (no) Syklopentenon-derivater
DK1178984T3 (da) 1-trifluormethyl-4-hydroxy-7-piperidinylaminomethylchroman-derivater
NO20015380D0 (no) Tio-oksindolderivater
DE59909774D1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate
DE50009668D1 (de) Echokompensationsvorrichtung

Legal Events

Date Code Title Description
MK1K Patent expired